Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Genovis Q1’22: Initial Take

2022-04-27

08:50

EN

FE

Erik Nordström

Filip Einarsson

Redeye regards Genovis’ Q1’22 report as solid and is encouraged to see continuously strong growth in the Enzyme business. Adjusted for the SEK 10m relating to the license agreement with Selecta, sales were in line with our expectations (SEK 22.6m versus our estimated SEK 22.9m).

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers